Mode
Text Size
Log in / Sign up

Medicinal mushroom-derived compounds show potential for managing oxidative stress and inflammation in ocular conditionsMedicinal mushrooms show promise for several common eye conditions

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that mushroom-derived compounds show potential for ocular health but require more clinical validation.

This narrative review explores the potential of medicinal mushroom-derived bioactive compounds, specifically polysaccharides and triterpenoids, in treating conditions such as dry eye disease, age-related macular degeneration, glaucoma, cataract, and other retinal disorders. The authors synthesize evidence categorized by clinical strength, noting that while beta-lactam antibiotics, cyclosporine A, and mycophenolate mofetil have Level 1 evidence, specific mushroom compounds like Isaria cicadae and Ganoderma lucidum currently hold Level 2 evidence.

Experimental data suggest these compounds may modulate oxidative stress, inflammation, intraocular pressure, fibrosis, and neuronal survival. However, other species such as Pleurotus spp., Hericium erinaceus, Wolfiporia extensa, and Polyporus umbellatus are currently supported only by Level 5 evidence. The review highlights a significant translational gap between traditional use or experimental findings and established clinical validation.

Clinical application is currently limited by marked heterogeneity in evidence levels and a lack of standardized formulations. While these compounds are a promising resource for ocular health, they remain under-validated. Further well-designed clinical trials are necessary to establish definitive therapeutic roles for these compounds in clinical practice.

How this fits prior evidence

This review addresses a gap in the management of oxidative stress and inflammation in ocular diseases. It specifically highlights how mushroom-derived compounds may modulate oxidative stress, which is a known mediator of retinal ganglion cell death and optic nerve damage in glaucoma.

Living with eye conditions like glaucoma or cataracts can be frustrating. New research is looking into how certain medicinal mushrooms might help. These mushrooms contain bioactive compounds, such as polysaccharides and triterpenoids, which may help reduce inflammation and protect nerves in the eye.

While some mushrooms like Isaria cicadae and Ganoderma lucidum show some promise for dry eye and age-related macular degeneration, the evidence is still early. Other mushrooms, like Pleurotus and Hericium erinaceus, have mostly been studied in labs or traditional settings. These studies suggest they could help manage eye pressure and fight oxidative stress.

It is important to remember that much of this research is still in the early stages. There is a big gap between what happens in a lab and what works in a clinic. Because the evidence is currently varied and not fully proven in humans, these mushrooms are considered a promising but under-validated resource for eye health.

What this means for you:
Mushroom-derived compounds show potential to fight eye inflammation, but more clinical trials are needed.

Common questions

Which eye conditions might these mushrooms help with?

The research looks at several conditions, including dry eye disease, age-related macular degeneration, glaucoma, cataracts, and other retinal disorders. Some specific mushrooms like Isaria cicadae and Ganoderma lucidum are being studied specifically for dry eye and age-related macular degeneration.

How do these mushrooms work to help the eyes?

The mushrooms contain compounds like polysaccharides and triterpenoids. These are thought to work by reducing inflammation, managing eye pressure, and protecting nerves. They may also help fight oxidative stress and prevent the buildup of scar tissue in the eye.

Is there enough evidence to use these for treatment today?

Not yet. While the compounds show promise in early research, there is a significant gap between laboratory results and clinical proof. Because the evidence is currently varied and not fully validated in humans, you should talk to your doctor about your treatment options.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Medicinal mushrooms have long been used in traditional medical systems, yet their ophthalmic relevance has only recently been explored. This narrative review provides, to our knowledge, an integrative mapping of medicinal mushroom-derived bioactive compounds in ophthalmology, with particular emphasis on their level of evidence across different ocular diseases. A structured search of PubMed, Scopus, Google Scholar and ScienceDirect (2001–2026) was conducted to identify experimental, clinical, and mechanistic studies addressing antioxidant, anti-inflammatory, immunomodulatory, neuroprotective and antifibrotic pathways in ocular tissues. The findings reveal a marked heterogeneity in evidence levels. A limited subset of fungal-derived compounds - primarily antimicrobial and immunomodulatory agents such as β-lactam antibiotics, cyclosporine A, and mycophenolate mofetil - are supported by high-level clinical evidence (Level 1), while emerging evidence (Level 2) is available for compounds such as Isaria cicadae in dry eye disease and Ganoderma lucidum in age-related macular degeneration. In contrast, the majority of medicinal mushrooms - including Pleurotus spp., Hericium erinaceus, Wolfiporia extensa, and Polyporus umbellatus - remain supported mainly by preclinical studies and traditional use (Level 5 evidence). Experimental data indicate that mushroom-derived polysaccharides and triterpenoids can modulate oxidative stress, inflammation, intraocular pressure, fibrosis, and neuronal survival. Additional compounds demonstrate potential in glaucoma, cataract, and retinal disorders through multitarget mechanisms. Overall, medicinal mushrooms represent a promising but still under-validated therapeutic resource in ophthalmology. The observed disparity between traditional use, experimental evidence, and clinical validation highlights a significant translational gap, underscoring the need for standardized formulations and well-designed clinical trials to enable evidence-based integration into ophthalmic practice.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.